Florida Senate - 2013                        COMMITTEE AMENDMENT
       Bill No. PCS (507672) for CS for SB 278
                                Barcode 155938                          
                              LEGISLATIVE ACTION                        
                    Senate             .             House              
                  Comm: RCS            .                                
                  03/21/2013           .                                

       The Committee on Appropriations (Richter) recommended the
    1         Senate Amendment (with title amendment)
    3         Delete everything after the enacting clause
    4  and insert:
    5         Section 1. Paragraph (b) of subsection (3) and subsection
    6  (4) of section 463.002, Florida Statutes, are amended,
    7  subsection (5) is renumbered as subsection (7) and amended,
    8  present subsections (6) through (10) are renumbered as
    9  subsections (8) through (12), respectively, and new subsections
   10  (5) and (6) are added to that section, to read:
   11         463.002 Definitions.—As used in this chapter, the term:
   12         (3)
   13         (b) A licensed practitioner who is not a certified
   14  optometrist shall be required to display at her or his place of
   15  practice a sign which states, “I am a Licensed Practitioner, not
   16  a Certified Optometrist, and I am not able to prescribe topical
   17  ocular pharmaceutical agents.”
   18         (4) “Certified optometrist” means a licensed practitioner
   19  authorized by the board to administer and prescribe topical
   20  ocular pharmaceutical agents.
   21         (5) “Ocular pharmaceutical agent” means a pharmaceutical
   22  agent that is administered topically or orally for the diagnosis
   23  or treatment of ocular conditions of the human eye and its
   24  appendages without the use of surgery or other invasive
   25  techniques.
   26         (6) “Surgery” means a procedure using an instrument,
   27  including a laser, scalpel, or needle, in which human tissue is
   28  cut, burned, scraped except as provided in s. 463.014(4), or
   29  vaporized, by incision, injection, ultrasound, laser, infusion,
   30  cryotherapy, or radiation. The term includes a procedure using
   31  an instrument which requires the closure of human tissue by
   32  suture, clamp, or other such device.
   33         (7)(5) “Optometry” means the diagnosis of conditions of the
   34  human eye and its appendages; the employment of any objective or
   35  subjective means or methods, including the administration of
   36  topical ocular pharmaceutical agents, for the purpose of
   37  determining the refractive powers of the human eyes, or any
   38  visual, muscular, neurological, or anatomic anomalies of the
   39  human eyes and their appendages; and the prescribing and
   40  employment of lenses, prisms, frames, mountings, contact lenses,
   41  orthoptic exercises, light frequencies, and any other means or
   42  methods, including topical ocular pharmaceutical agents, for the
   43  correction, remedy, or relief of any insufficiencies or abnormal
   44  conditions of the human eyes and their appendages.
   45         Section 2. Paragraph (g) of subsection (1) of section
   46  463.005, Florida Statutes, is amended to read:
   47         463.005 Authority of the board.—
   48         (1) The Board of Optometry has authority to adopt rules
   49  pursuant to ss. 120.536 (1) and 120.54 to implement the
   50  provisions of this chapter conferring duties upon it. Such rules
   51  shall include, but not be limited to, rules relating to:
   52         (g) Administration and prescription of topical ocular
   53  pharmaceutical agents.
   54         Section 3. Section 463.0055, Florida Statutes, is amended
   55  to read:
   56         463.0055 Administration and prescription of topical ocular
   57  pharmaceutical agents; committee.—
   58         (1)(a) Certified optometrists may administer and prescribe
   59  topical ocular pharmaceutical agents as provided in this section
   60  for the diagnosis and treatment of ocular conditions of the
   61  human eye and its appendages without the use of surgery or other
   62  invasive techniques. However, a licensed practitioner who is not
   63  certified may use topically applied anesthetics solely for the
   64  purpose of glaucoma examinations, but is otherwise prohibited
   65  from administering or prescribing topical ocular pharmaceutical
   66  agents.
   67         (b) Before a certified optometrist may administer or
   68  prescribe oral ocular pharmaceutical agents, the certified
   69  optometrist must provide proof to the department of successful
   70  completion of a course and subsequent examination, approved by
   71  the board, on general and ocular pharmaceutical agents and the
   72  side effects of those agents. The course shall consist of 20
   73  contact hours, all of which may be web-based. The first course
   74  and examination shall be presented by October 1, 2013, and shall
   75  be administered at least annually thereafter. The course and
   76  examination shall be developed and offered jointly by a
   77  statewide professional association of physicians in this state
   78  accredited to provide educational activities designated for the
   79  American Medical Association Physician’s Recognition Award (AMA
   80  PRA) Category 1 credit and a statewide professional association
   81  of licensed practitioners which provides board-approved
   82  continuing education on an annual basis. The board shall review
   83  and approve the content of the initial course and examination if
   84  the board determines that the course and examination adequately
   85  and reliably satisfy the criteria set forth in this section. The
   86  board shall thereafter annually review and approve the course
   87  and examination if the board determines that the content
   88  continues to adequately and reliably satisfy the criteria set
   89  forth in this section. Successful completion of the board
   90  approved course and examination may be used by a certified
   91  optometrist to satisfy 20 hours of the continuing education
   92  requirements in s. 463.007(3), only for the biennial period in
   93  which the board-approved course and examination are taken. If a
   94  certified optometrist does not complete a board-approved course
   95  and examination under this section, the certified optometrist is
   96  only authorized to administer and prescribe topical ocular
   97  pharmaceutical agents.
   98         (2)(a) The board shall establish a formulary of topical
   99  ocular pharmaceutical agents that may be prescribed and
  100  administered by a certified optometrist. There is hereby created
  101  a committee composed of two optometrists licensed pursuant to
  102  this chapter, appointed by the Board of Optometry, two board
  103  certified ophthalmologists licensed pursuant to chapter 458 or
  104  chapter 459, appointed by the Board of Medicine, and one
  105  additional person with a doctorate degree in pharmacology who is
  106  not licensed pursuant to chapter 458, chapter 459, or this
  107  chapter, appointed by the State Surgeon General. The committee
  108  shall review requests for additions to, deletions from, or
  109  modifications of a formulary of topical ocular pharmaceutical
  110  agents for administration and prescription by certified
  111  optometrists and shall provide to the board advisory opinions
  112  and recommendations on such requests. The formulary shall
  113  consist of those topical ocular pharmaceutical agents that are
  114  appropriate to treat or diagnose ocular diseases and disorders
  115  and that which the certified optometrist is qualified to use in
  116  the practice of optometry. The board shall establish, add to,
  117  delete from, or modify the topical formulary by rule.
  118  Notwithstanding any provision of chapter 120 to the contrary,
  119  the topical formulary rule becomes shall become effective 60
  120  days from the date it is filed with the Secretary of State.
  121         (b) The formulary may be added to, deleted from, or
  122  modified according to the procedure described in paragraph (a).
  123  Any person who requests an addition, deletion, or modification
  124  of an authorized topical ocular pharmaceutical agent shall have
  125  the burden of proof to show cause why such addition, deletion,
  126  or modification should be made.
  127         (c) The State Surgeon General shall have standing to
  128  challenge any rule or proposed rule of the board pursuant to s.
  129  120.56. In addition to challenges for any invalid exercise of
  130  delegated legislative authority, the administrative law judge,
  131  upon such a challenge by the State Surgeon General, may declare
  132  all or part of a rule or proposed rule invalid if it:
  133         1. Does not protect the public from any significant and
  134  discernible harm or damages;
  135         2. Unreasonably restricts competition or the availability
  136  of professional services in the state or in a significant part
  137  of the state; or
  138         3. Unnecessarily increases the cost of professional
  139  services without a corresponding or equivalent public benefit.
  141  However, there shall not be created a presumption of the
  142  existence of any of the conditions cited in this subsection in
  143  the event that the rule or proposed rule is challenged.
  144         (d) Upon adoption of the formulary required by this
  145  section, and upon each addition, deletion, or modification to
  146  the formulary, the board shall mail a copy of the amended
  147  formulary to each certified optometrist and to each pharmacy
  148  licensed by the state.
  149         (3) In addition to the formulary of topical ocular
  150  pharmaceutical agents established by rule of the board, there is
  151  created a statutory formulary of oral ocular pharmaceutical
  152  agents, which includes the following agents:
  153         (a) The following analgesics or their generic or
  154  therapeutic equivalents, which may not be administered or
  155  prescribed for more than 72 hours without consultation with a
  156  physician licensed under chapter 458 or chapter 459 who is
  157  skilled in diseases of the eye:
  158         1. Tramadol hydrochloride.
  159         2. Acetaminophen 300 mg with No. 3 codeine phosphate 30 mg.
  160         (b) The following antibiotics or their generic or
  161  therapeutic equivalents:
  162         1. Amoxicillin with or without clavulanic acid.
  163         2. Azithromycin.
  164         3. Erythromycin.
  165         4. Dicloxacillin.
  166         5. Doxycycline/Tetracycline.
  167         6. Keflex.
  168         7. Minocycline.
  169         (c) The following antivirals or their generic or
  170  therapeutic equivalents:
  171         1. Acyclovir.
  172         2. Famciclovir.
  173         3. Valacyclovir.
  174         (d) The following oral anti-glaucoma agents or their
  175  generic or therapeutic equivalents, which may not be
  176  administered or prescribed for more than 72 hours:
  177         1. Acetazolamide.
  178         2. Methazolamide.
  180  Any oral ocular pharmaceutical agent that is listed in the
  181  statutory formulary set forth in this subsection and that is
  182  subsequently determined by the United States Food and Drug
  183  Administration to be unsafe for administration or prescription
  184  shall be considered to have been deleted from the formulary of
  185  oral ocular pharmaceutical agents. The oral ocular
  186  pharmaceutical agents on the statutory formulary set forth in
  187  this subsection may not otherwise be deleted by the board, the
  188  department, or the State Surgeon General.
  189         (4)(3) A certified optometrist shall be issued a prescriber
  190  number by the board. Any prescription written by a certified
  191  optometrist for an a topical ocular pharmaceutical agent
  192  pursuant to this section shall have the prescriber number
  193  printed thereon. A certified optometrist may not administer or
  194  prescribe:
  195         (a) A controlled substance listed in Schedule III, Schedule
  196  IV, or Schedule V of s. 893.03, except for an oral analgesic
  197  placed on the formulary pursuant to this section for the relief
  198  of pain due to ocular conditions of the eye and its appendages.
  199         (b) A controlled substance for the treatment of chronic
  200  nonmalignant pain as defined in s. 456.44(1)(e).
  201         Section 4. Subsection (3) of section 463.0057, Florida
  202  Statutes, is amended to read:
  203         463.0057 Optometric faculty certificate.—
  204         (3) The holder of a faculty certificate may engage in the
  205  practice of optometry as permitted by this section, but may not
  206  administer or prescribe topical ocular pharmaceutical agents
  207  unless the certificateholder has satisfied the requirements of
  208  s. 463.006(1)(b)4. and 5. If a certificateholder wishes to
  209  administer or prescribe oral ocular pharmaceutical agents, the
  210  certificateholder must also satisfy the requirements of s.
  211  463.0055(1)(b).
  212         Section 5. Subsections (2) and (3) of section 463.006,
  213  Florida Statutes, are amended to read:
  214         463.006 Licensure and certification by examination.—
  215         (2) The examination shall consist of the appropriate
  216  subjects, including applicable state laws and rules and general
  217  and ocular pharmacology with emphasis on the use topical
  218  application and side effects of ocular pharmaceutical agents.
  219  The board may by rule substitute a national examination as part
  220  or all of the examination and may by rule offer a practical
  221  examination in addition to the written examination.
  222         (3) Each applicant who successfully passes the examination
  223  and otherwise meets the requirements of this chapter is entitled
  224  to be licensed as a practitioner and to be certified to
  225  administer and prescribe topical ocular pharmaceutical agents in
  226  the diagnosis and treatment of ocular conditions.
  227         Section 6. Subsections (10) and (11) are added to section
  228  463.0135, Florida Statutes, to read:
  229         463.0135 Standards of practice.—
  230         (10) A certified optometrist is authorized to perform any
  231  eye examination, including a dilated examination, required or
  232  authorized by chapter 548 or by rules adopted to implement that
  233  chapter.
  234         (11) Co-management of postoperative care shall be conducted
  235  pursuant to the requirements of this section and a patient
  236  specific transfer of care letter that governs the relationship
  237  between the physician who performed the surgery and the licensed
  238  practitioner. The patient must be fully informed of, and consent
  239  in writing to, the co-management relationship for his or her
  240  care. The transfer of care letter shall confirm that it is not
  241  medically necessary for the physician who performed the surgery
  242  to provide such postoperative care to the patient and that it is
  243  clinically appropriate for the licensed practitioner to provide
  244  such postoperative care. Before co-management of postoperative
  245  care commences, the patient shall be informed in writing that he
  246  or she has the right to be seen during the entire postoperative
  247  period by the physician who performed the surgery. In addition,
  248  the patient must be informed of the fees, if any, to be charged
  249  by the licensed practitioner and the physician performing the
  250  surgery, and must be provided with an accurate and comprehensive
  251  itemized statement of the specific postoperative care services
  252  that the physician performing the surgery and the licensed
  253  practitioner render, along with the charge for each service.
  254         Section 7. Subsections (3) and (4) of section 463.014,
  255  Florida Statutes, are amended to read:
  256         463.014 Certain acts prohibited.—
  257         (3) Prescribing, ordering, dispensing, administering,
  258  supplying, selling, or giving any drug for the purpose of
  259  treating a systemic disease systemic drugs by a licensed
  260  practitioner is prohibited. However, a certified optometrist is
  261  permitted to use commonly accepted means or methods to
  262  immediately address incidents of anaphylaxis.
  263         (4) Surgery of any kind, including the use of lasers, is
  264  expressly prohibited. Certified optometrists may remove
  265  superficial foreign bodies. For the purposes of this subsection,
  266  the term “superficial foreign bodies” means any foreign matter
  267  that is embedded in the conjunctiva or cornea but that which has
  268  not penetrated the globe. Notwithstanding the definition of
  269  surgery as provided in s. 463.002(6), a certified optometrist is
  270  not prohibited from providing any optometric care within the
  271  practice of optometry as defined in s. 463.002(7), such as
  272  removing an eyelash by epilation, probing an uninflamed tear
  273  duct in a patient 18 years of age or older, blocking the puncta
  274  by plug, or superficial scraping for the purpose of removing
  275  damaged epithelial tissue or superficial foreign bodies or
  276  taking a culture of the surface of the cornea or conjunctiva.
  277         Section 8. Section 463.0141, Florida Statutes, is created
  278  to read:
  279         463.0141 Reports of adverse incidents in the practice of
  280  optometry.—
  281         (1) Effective January 1, 2014, an adverse incident
  282  occurring in the practice of optometry must be reported to the
  283  department in accordance with this section.
  284         (2) The required notification must be in writing and
  285  submitted to the department by certified mail. The required
  286  notification must be postmarked within 15 days after the adverse
  287  incident if the adverse incident occurs when the patient is at
  288  the office of the licensed practitioner. If the adverse incident
  289  occurs when the patient is not at the office of the licensed
  290  practitioner, the required notification must be postmarked
  291  within 15 days after the licensed practitioner discovers, or
  292  reasonably should have discovered, the occurrence of the adverse
  293  incident.
  294         (3) For purposes of notification to the department, the
  295  term “adverse incident,” as used in this section, means any of
  296  the following events when it is reasonable to believe that the
  297  event is attributable to the prescription of an oral ocular
  298  pharmaceutical agent by the licensed practitioner:
  299         (a) Any condition that requires the transfer of a patient
  300  to a hospital licensed under chapter 395.
  301         (b) Any condition that requires the patient to obtain care
  302  from a physician licensed under chapter 458 or chapter 459,
  303  other than a referral or a consultation required under this
  304  chapter.
  305         (c) Permanent physical injury to the patient.
  306         (d) Partial or complete permanent loss of sight by the
  307  patient.
  308         (e) Death of the patient.
  309         (4) The department shall review each incident and determine
  310  whether it potentially involved conduct by the licensed
  311  practitioner who may be subject to disciplinary action, in which
  312  event s. 456.073 applies. Disciplinary action, if any, shall be
  313  taken by the board.
  314         Section 9. Subsection (1) of section 483.035, Florida
  315  Statutes, is amended to read:
  316         483.035 Clinical laboratories operated by practitioners for
  317  exclusive use; licensure and regulation.—
  318         (1) A clinical laboratory operated by one or more
  319  practitioners licensed under chapter 458, chapter 459, chapter
  320  460, chapter 461, chapter 462, chapter 463, or chapter 466,
  321  exclusively in connection with the diagnosis and treatment of
  322  their own patients, must be licensed under this part and must
  323  comply with the provisions of this part, except that the agency
  324  shall adopt rules for staffing, for personnel, including
  325  education and training of personnel, for proficiency testing,
  326  and for construction standards relating to the licensure and
  327  operation of the laboratory based upon and not exceeding the
  328  same standards contained in the federal Clinical Laboratory
  329  Improvement Amendments of 1988 and the federal regulations
  330  adopted thereunder.
  331         Section 10. Subsection (7) of section 483.041, Florida
  332  Statutes, is amended to read:
  333         483.041 Definitions.—As used in this part, the term:
  334         (7) “Licensed practitioner” means a physician licensed
  335  under chapter 458, chapter 459, chapter 460, or chapter 461; a
  336  certified optometrist licensed under chapter 463; a dentist
  337  licensed under chapter 466; a person licensed under chapter 462;
  338  or an advanced registered nurse practitioner licensed under part
  339  I of chapter 464; or a duly licensed practitioner from another
  340  state licensed under similar statutes who orders examinations on
  341  materials or specimens for nonresidents of the State of Florida,
  342  but who reside in the same state as the requesting licensed
  343  practitioner.
  344         Section 11. Subsection (5) of section 483.181, Florida
  345  Statutes, is amended to read:
  346         483.181 Acceptance, collection, identification, and
  347  examination of specimens.—
  348         (5) A clinical laboratory licensed under this part must
  349  accept a human specimen submitted for examination by a
  350  practitioner licensed under chapter 458, chapter 459, chapter
  351  460, chapter 461, chapter 462, chapter 463, s. 464.012, or
  352  chapter 466, if the specimen and test are the type performed by
  353  the clinical laboratory. A clinical laboratory may only refuse a
  354  specimen based upon a history of nonpayment for services by the
  355  practitioner. A clinical laboratory shall not charge different
  356  prices for tests based upon the chapter under which a
  357  practitioner submitting a specimen for testing is licensed.
  358         Section 12. Subsection (21) of section 893.02, Florida
  359  Statutes, is amended to read:
  360         893.02 Definitions.—The following words and phrases as used
  361  in this chapter shall have the following meanings, unless the
  362  context otherwise requires:
  363         (21) “Practitioner” means a physician licensed pursuant to
  364  chapter 458, a dentist licensed pursuant to chapter 466, a
  365  veterinarian licensed pursuant to chapter 474, an osteopathic
  366  physician licensed pursuant to chapter 459, a naturopath
  367  licensed pursuant to chapter 462, a certified optometrist
  368  licensed pursuant to chapter 463, or a podiatric physician
  369  licensed pursuant to chapter 461, provided such practitioner
  370  holds a valid federal controlled substance registry number.
  371         Section 13. Subsection (1) of section 893.05, Florida
  372  Statutes, is amended to read:
  373         893.05 Practitioners and persons administering controlled
  374  substances in their absence.—
  375         (1) A practitioner, in good faith and in the course of his
  376  or her professional practice only, may prescribe, administer,
  377  dispense, mix, or otherwise prepare a controlled substance, or
  378  the practitioner may cause the same to be administered by a
  379  licensed nurse or an intern practitioner under his or her
  380  direction and supervision only. A veterinarian may so prescribe,
  381  administer, dispense, mix, or prepare a controlled substance for
  382  use on animals only, and may cause it to be administered by an
  383  assistant or orderly under the veterinarian’s direction and
  384  supervision only. A certified optometrist licensed under chapter
  385  463 may not administer or prescribe a controlled substance
  386  listed in Schedule I or Schedule II of s. 893.03.
  387         Section 14. Paragraph (d) of subsection (1) of section
  388  893.055, Florida Statutes, is amended to read:
  389         893.055 Prescription drug monitoring program.—
  390         (1) As used in this section, the term:
  391         (d) “Health care practitioner” or “practitioner” means any
  392  practitioner who is subject to licensure or regulation by the
  393  department under chapter 458, chapter 459, chapter 461, chapter
  394  462, chapter 463, chapter 464, chapter 465, or chapter 466.
  395         Section 15. Section 463.009, Florida Statutes, is amended
  396  to read:
  397         463.009 Supportive personnel.—No person other than a
  398  licensed practitioner may engage in the practice of optometry as
  399  defined in s. 463.002(7) 463.002(5). Except as provided in this
  400  section, under no circumstances shall nonlicensed supportive
  401  personnel be delegated diagnosis or treatment duties; however,
  402  such personnel may perform data gathering, preliminary testing,
  403  prescribed visual therapy, and related duties under the direct
  404  supervision of the licensed practitioner. Nonlicensed personnel,
  405  who need not be employees of the licensed practitioner, may
  406  perform ministerial duties, tasks, and functions assigned to
  407  them by and performed under the general supervision of a
  408  licensed practitioner, including obtaining information from
  409  consumers for the purpose of making appointments for the
  410  licensed practitioner. The licensed practitioner shall be
  411  responsible for all delegated acts performed by persons under
  412  her or his direct and general supervision.
  413         Section 16. Subsection (19) of section 641.31, Florida
  414  Statutes, is amended to read:
  415         641.31 Health maintenance contracts.—
  416         (19) Notwithstanding any other provision of law, health
  417  maintenance policies or contracts which provide coverage,
  418  benefits, or services as described in s. 463.002(7) 463.002(5),
  419  shall offer to the subscriber the services of an optometrist
  420  licensed pursuant to chapter 463.
  421         Section 17. This act shall take effect July 1, 2013.
  423  ================= T I T L E  A M E N D M E N T ================
  424         And the title is amended as follows:
  425         Delete everything before the enacting clause
  426  and insert:
  427                        A bill to be entitled                      
  428         An act relating to the practice of optometry; amending
  429         s. 463.002, F.S.; revising and providing definitions;
  430         authorizing a certified optometrist to administer and
  431         prescribe ocular pharmaceutical agents; amending s.
  432         463.005, F.S.; authorizing the Board of Optometry to
  433         adopt rules relating to the administration and
  434         prescription of ocular pharmaceutical agents; amending
  435         s. 463.0055, F.S.; requiring a certified optometrist
  436         to complete a board-approved course and examination on
  437         general and ocular pharmaceutical agents before
  438         administering or prescribing those agents; requiring
  439         the certified optometrist to provide proof to the
  440         department of successful completion of the course and
  441         examination; authorizing that successful completion of
  442         the course and examination be used to satisfy certain
  443         continuing education requirements; requiring the board
  444         to establish a formulary of topical ocular
  445         pharmaceutical agents that may be prescribed and
  446         administered by certified optometrists; deleting
  447         provisions with respect to a committee; establishing a
  448         statutory formulary of oral ocular pharmaceutical
  449         agents; prohibiting a certified optometrist from
  450         administering or prescribing certain controlled
  451         substances; amending s. 463.0057, F.S.; providing
  452         conditions under which the holder of an optometric
  453         faculty certificate may administer and prescribe oral
  454         ocular pharmaceutical agents; amending s. 463.006,
  455         F.S.; revising provisions relating to licensure and
  456         certification of optometrists, to conform; amending s.
  457         463.0135, F.S.; authorizing a certified optometrist to
  458         perform certain eye examinations; requiring a transfer
  459         of care letter for the co-management of postoperative
  460         care; requiring patient consent; requiring the patient
  461         to be informed of the fees and provided an itemized
  462         statement of services; amending s. 463.014, F.S.;
  463         prohibiting a licensed practitioner of optometry from
  464         providing any drug for the purpose of treating a
  465         systemic disease; specifying procedures that a
  466         certified optometrist is authorized to perform;
  467         creating s. 463.0141, F.S.; requiring the reporting of
  468         adverse incidents in the practice of optometry to the
  469         department according to specified procedures;
  470         providing a definition; requiring the department to
  471         review the conduct of licensed practitioners with
  472         respect to adverse incidents, to which disciplinary
  473         action may apply; amending s. 483.035, F.S.; requiring
  474         a clinical laboratory operated by a licensed
  475         practitioner of optometry to be licensed under
  476         Optometry Practice Act; amending s. 483.041, F.S.;
  477         revising the definition of the term “licensed
  478         practitioner” to include certified optometrists;
  479         amending s. 483.181, F.S.; providing for an
  480         optometrist to accept a human specimen for
  481         examination, under certain conditions; amending s.
  482         893.02, F.S.; redefining the term “practitioner” to
  483         include certified optometrists; amending s. 893.05,
  484         F.S.; prohibiting a certified optometrist from
  485         administering or prescribing certain controlled
  486         substances; amending s. 893.055, F.S.; revising the
  487         term “health care practitioner” to include certified
  488         optometrists for purposes of the prescription drug
  489         monitoring program; amending ss. 463.009 and 641.31,
  490         F.S.; conforming cross-references; providing an
  491         effective date.